Completed PHASE3 INTERVENTIONAL NCT00036543

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Sponsor: Abbott

Conditions Prostate Cancer

Interventions Atrasentan

Updated 6 times since 2017 Last updated: Aug 10, 2006 Started: May 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Prostate Cancer and is currently completed. Abbott leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aarau, Switzerland , Aberdeen, United Kingdom , Albany, United States , Allentown, United States , Amsterdam, Netherlands , Anchorage, United States , Antwerp, Belgium , Arnhem, Netherlands , Athens, Greece and 191 more locations